An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
Diabetes Mellitus, Type 2, Chronic Renal Insufficiency
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Type 2 Diabetes Mellitus and Chronic Renal Insufficiency
Eligibility Criteria
Inclusion Criteria: Patients who are at least 18 years of age diagnosed with type 2 diabetes mellitus (T2DM) (a specific type of diabetes). Patient has renal (kidney) insufficiency (inadequate kidney function) Exclusion Criteria: Patient has had heart problems (such as a heart attack or chest pain) or stroke within the past 6 months or any condition or therapy which, in the opinion of the investigator, may not be in the patient's best interest to participate. Pregnant or breast feeding
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Sitagliptin
Placebo
Participants in the Sitagliptin treatment sequence will receive sitagliptin in Phase A and placebo to glipizide in Phase B.
Participants in the Placebo treatment sequence will receive placebo to sitagliptin in Phase A and glipizide in Phase B.